Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.08
Nov 17 • 11:17 AM ET Dollar change-0.12 Percentage change(-9.66%)
Index
-
Market Cap
81.20M
Enterprise Value
-21.22M
Income
-88.53M
Sales
0.00M
Book/sh
0.76
Cash/sh
1.36
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
54
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.42
P/C
0.79
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.81
Current Ratio
9.81
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-1.53
EPS next Y
-0.88
EPS next Q
-0.27
EPS this Y
10.64%
EPS next Y
33.84%
EPS next 5Y
24.38%
EPS past 3/5Y
2.74% -13.98%
Sales past 3/5Y
- -
EPS Y/Y TTM
3.11%
Sales Y/Y TTM
-
EPS Q/Q
-30.60%
Sales Q/Q
-
Insider Own
6.90%
Insider Trans
0.00%
Inst Own
48.23%
Inst Trans
-4.52%
ROA
-72.20%
ROE
-99.42%
ROIC
-155.03%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-15.49%
SMA50
-22.02%
SMA200
-17.84%
Trades
Shs Outstand
75.53M
Shs Float
70.32M
52W High
1.91 -43.72%
52W Low
1.02 5.39%
Volatility
6.98% 7.97%
ATR (14)
0.11
RSI (14)
36.43
Beta
1.52
Rel Volume
1.38
Avg Volume
682.84K
Volume
293,246
Perf Week
-11.89%
Perf Month
-14.34%
Perf Quarter
-16.02%
Perf Half Y
-17.94%
Perf YTD
-14.00%
Perf Year
-24.30%
Perf 3Y
-57.00%
Perf 5Y
-95.57%
Perf 10Y
-
Prev Close
1.19
Price
1.08
Change %
-9.66%
Consensus
Strong Buy
Avg. Price Target
$4.00
Implied Upside
+272.1%
Analysts10incl. previous ratings
Rating Distribution10 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2026Initiated
LLadenburg Thalmann
Buy$3+179.1%
Nov 08, 2024Upgrade
OPY logoOOppenheimer
Perform → Outperform$6+458.1%
May 13, 2024Initiated
CCraig Hallum
Buy$6+458.1%
Apr 12, 2024Initiated
JEF logoJJefferies
Buy$5+365.1%
Dec 27, 2023Initiated
LLadenburg Thalmann
Buy$7+551.2%
Mar 02, 2022Upgrade
OPY logoOOppenheimer
Perform → Outperform$30+2,690.7%
Sep 22, 2021Upgrade
GS logoGGoldman
Neutral → Buy$35 → $43+3,900.0%
Aug 19, 2021Initiated
OPY logoOOppenheimer
Perform
Aug 02, 2021Initiated
GGuggenheim
Buy$56+5,109.3%
Jul 29, 2021Initiated
HH.C. Wainwright
Buy$63+5,760.5%
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
Co-FounderDr. David H. Mack Ph.D.
Co-FounderDr. Arnold J. Levine Ph.D.
General CounselMr. Robert Ticktin J.D.
Chief Development OfficerDr. Deepika Jalota Pharm.D.
CFO & Principal Financial & Accounting OfficerMr. Michael Carulli